COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021-2022.
Africa
COVID-19 vaccines
COVID-19/mortality
SARS-CoV-2
Zambia
vaccine efficacy
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
29
07
2022
accepted:
08
09
2022
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
6
10
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) vaccines are highly effective for reducing severe disease and mortality. However, vaccine effectiveness data are limited from Sub-Saharan Africa. We report COVID-19 vaccine effectiveness against progression to in-hospital mortality in Zambia. We conducted a retrospective cohort study among admitted patients at 8 COVID-19 treatment centers across Zambia during April 2021 through March 2022, when the Delta and Omicron variants were circulating. Patient demographic and clinical information including vaccination status and hospitalization outcome (discharged or died) were collected. Multivariable logistic regression was used to assess the odds of in-hospital mortality by vaccination status, adjusted for age, sex, number of comorbid conditions, disease severity, hospitalization month, and COVID-19 treatment center. Vaccine effectiveness of ≥1 vaccine dose was calculated from the adjusted odds ratio. Among 1653 patients with data on their vaccination status and hospitalization outcome, 365 (22.1%) died. Overall, 236 (14.3%) patients had received ≥1 vaccine dose before hospital admission. Of the patients who had received ≥1 vaccine dose, 22 (9.3%) died compared with 343 (24.2%) among unvaccinated patients ( Among patients admitted to COVID-19 treatment centers in Zambia, COVID-19 vaccination was associated with lower progression to in-hospital mortality. These data are consistent with evidence from other countries demonstrating the benefit of COVID-19 vaccination against severe complications. Vaccination is a critical tool for reducing the consequences of COVID-19 in Zambia.
Sections du résumé
Background
UNASSIGNED
Coronavirus disease 2019 (COVID-19) vaccines are highly effective for reducing severe disease and mortality. However, vaccine effectiveness data are limited from Sub-Saharan Africa. We report COVID-19 vaccine effectiveness against progression to in-hospital mortality in Zambia.
Methods
UNASSIGNED
We conducted a retrospective cohort study among admitted patients at 8 COVID-19 treatment centers across Zambia during April 2021 through March 2022, when the Delta and Omicron variants were circulating. Patient demographic and clinical information including vaccination status and hospitalization outcome (discharged or died) were collected. Multivariable logistic regression was used to assess the odds of in-hospital mortality by vaccination status, adjusted for age, sex, number of comorbid conditions, disease severity, hospitalization month, and COVID-19 treatment center. Vaccine effectiveness of ≥1 vaccine dose was calculated from the adjusted odds ratio.
Results
UNASSIGNED
Among 1653 patients with data on their vaccination status and hospitalization outcome, 365 (22.1%) died. Overall, 236 (14.3%) patients had received ≥1 vaccine dose before hospital admission. Of the patients who had received ≥1 vaccine dose, 22 (9.3%) died compared with 343 (24.2%) among unvaccinated patients (
Conclusions
UNASSIGNED
Among patients admitted to COVID-19 treatment centers in Zambia, COVID-19 vaccination was associated with lower progression to in-hospital mortality. These data are consistent with evidence from other countries demonstrating the benefit of COVID-19 vaccination against severe complications. Vaccination is a critical tool for reducing the consequences of COVID-19 in Zambia.
Identifiants
pubmed: 36196297
doi: 10.1093/ofid/ofac469
pii: ofac469
pmc: PMC9522674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac469Informations de copyright
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
EClinicalMedicine. 2022 Mar 24;46:101360
pubmed: 35340627
Lancet HIV. 2021 Sep;8(9):e554-e567
pubmed: 34363789
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):459-465
pubmed: 35324878
MMWR Morb Mortal Wkly Rep. 2021 Jun 04;70(22):807-810
pubmed: 34081684
Lancet. 2021 Apr 3;397(10281):1265-1275
pubmed: 33773118
Am J Trop Med Hyg. 2022 Sep 12;:
pubmed: 36096406
Int J Infect Dis. 2022 Jan;114:252-260
pubmed: 34800687
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):549-555
pubmed: 35421077
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35998978
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-6
pubmed: 34227914
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223
pubmed: 35143466
Lancet Infect Dis. 2022 Sep;22(9):1293-1302
pubmed: 35753318
Lancet Glob Health. 2021 Jun;9(6):e773-e781
pubmed: 33711262
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
N Engl J Med. 2022 Mar 10;386(10):933-941
pubmed: 35020982
JAMA Netw Open. 2022 Mar 1;5(3):e222959
pubmed: 35297969
Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S159-S166
pubmed: 35675695
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
Lancet. 2022 Mar 19;399(10330):1141-1153
pubmed: 35305740